Coronavirus (COVID-19)
Learn more
Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer (AXLerate-OC)
This is a randomize, double-blind Phase 3 study to compare the efficacy and safety of AVB-S6-500 in combination with paclitaxel (Pac) versus placebo in combination with Pac in patients with platinum resistant recurrent ovarian cancer.
Eligibility Criteria:
This study is for patients age 18 and older.
Available at: Hartford Hospital, Hospital of Central Connecticut.
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
Sign up for text alerts / Text MoreLife to 31996.